auto transplant vs chimeric antigen receptor t-cell therapy for relapsed dlbcl in partial remission
Published 2 years ago • 246 plays • Length 45:36Download video MP4
Download video MP3
Similar videos
-
45:36
autologous transplant vs chimeric antigen rec. t-cell therapy for relapsed dlbcl in partial rem.
-
51:15
management of relapsed dlbcl in era of car t therapy
-
1:31
car-t therapy versus autosct in dlbcl
-
55:58
role of cd19 car t cells in second line large b cell lymphoma
-
49:10
car t cell therapy for relapsed lymphoma: journey from being a patient to a survivor
-
39:11
car-t cell therapy for adult all
-
30:02
car-t cell therapy in lymphoma
-
2:06
car-t therapy vs autologous transplantation in r/r dlbcl
-
1:38:01
post #ash21 by the iach: car-t cells
-
54:11
car t-cells in lymphoma: new advances and practical aspects
-
48:12
outcomes of patients with aggressive b-cell lymphoma after failure of anti-cd19 car t-cell therapy
-
23:57
iach 2019: car t cell therapy - how to set up a clinical unit
-
58:13
optimising transplant outcome in adults allografted for aml
-
53:15
cd19 car t cells in lymphoid malignancies – 2018 update
-
23:03
car-t cells in multiple myeloma
-
8:54
stephen j. schuster, md: tisagenlecleucel promising in relapsed/refractory dlbcl
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
1:16:35
bi-and tri-specific antibodies in non-hodgkin lymphoma: current data and perspectives
-
47:52
gut microbiome correlates of response and toxicity following anti cd19 car t cell therapy